DBP

Double Bond Pharmaceutical expands the cooperation with Alexandrov Cancer Centre to identify biomarkers for Temodex

Wed, Feb 15, 2017 08:05 CET

As previously described, DBP has recently started an extensive partnership agreement with N. N. Alexandrov National Centre of Belarus on Temodex. Now the cooperation is deepened further and includes the identification of potential biomarkers for Temodex. "Biomarkers are absolutely central in the development of modern drugs, especially as so-called personalized medicine becomes increasingly vital in the pharmaceutical world. We see a great potential and opportunities in effective development of biomarkers, - says Igor Lokot, CEO of DBP. - This ensures further the therapeutic value of

Double Bond Pharmaceutical AB and N.N. Alexandrov National Cancer Centre of Belarus has entered into agreement about clinical use of Temodex.

Tue, Jan 10, 2017 11:17 CET

DBP announced 5 december 2016 that the company started a collaboration with N. N. Alexandrov National Cancer Centre of Belarus. The main goal was to get access to skills and resources that are relevant to the development of DBP’s products including Temodex that is a drug against brain cancer. The cooperation has been now further developed through a partnership agreement concerning a follow-up of patients with brain tumors treated in Belarus in N. N. Alexandrov National Centre, which will accelerate the process of making Temodex commercially viable worldwide. Under the agreement, all

Share

Double Bond Pharmaceutical expands the cooperation with Alexandrov Cancer Centre to identify biomarkers for Temodex

Double Bond Pharmaceutical AB and N.N. Alexandrov National Cancer Centre of Belarus has entered into agreement about clinical use of Temodex.

Subscribe